Anastasiia V Petrokovskaia
Anastasiia V Petrokovskaia has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Ada R. Artemenko
I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia
2 shared publications - Elena Vladimirovna Orekhova
Moscow State University of Psychology and Education
2 shared publications - Tatiana A. Stroganova
Moscow State University of Psychology and Education
2 shared publications - Tatiana S. Obukhova
Moscow State University of Psychology and Education
2 shared publications A.O. Prokofiev
1 shared publication- Andrew Kozlov
Burdenko Neurosurgical Center
1 shared publication
Latest Publications
- 15 April 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (3) , 68-73
Frequency of 5q spinal muscular atrophy in adults with unspecified neuromuscular diseases
Objective. To assess the prevalence of 5q spinal muscular atrophy (SMA) among adult patients with undifferentiated neuromuscular disorders. Material and methods. Prospective study of 50 patients (19—78 years) presenting ≥1 feature of 5q SMA: areflexia, proximal weakness, fasciculations, neurogenic EMG changes, atrophy, calf hypertrophy, or elevated creatine kinase (CK). Molecular testing (MLPA/melting curve analysis of SMN1/SMN2) was performed. Results. 5q SMA was confirmed in one female patient (2% [95% CI 0.05—10.6]), who was found to have a homozygous deletion of exons 7—8 in the SMN1 gene. Her clinical presentation included proximal lower limb weakness and neurogenic EMG changes, but she lacked areflexia and had normal CK levels. For 29 years, she had been misdiagnosed with «unspecified myopathy»(G72.9). Conclusion. The findings highlight the need to include 5q SMA in the differential diagnosis of adult patients with undifferentiated neuromuscular disorders. Optimizing diagnostic algorithms and enhancing epidemiological monitoring in this age group are essential to reduce diagnostic delays.
- 15 April 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (3) , 68-73
Frequency of 5q spinal muscular atrophy in adults with unspecified neuromuscular diseases
Objective. To assess the prevalence of 5q spinal muscular atrophy (SMA) among adult patients with undifferentiated neuromuscular disorders. Material and methods. Prospective study of 50 patients (19—78 years) presenting ≥1 feature of 5q SMA: areflexia, proximal weakness, fasciculations, neurogenic EMG changes, atrophy, calf hypertrophy, or elevated creatine kinase (CK). Molecular testing (MLPA/melting curve analysis of SMN1/SMN2) was performed. Results. 5q SMA was confirmed in one female patient (2% [95% CI 0.05—10.6]), who was found to have a homozygous deletion of exons 7—8 in the SMN1 gene. Her clinical presentation included proximal lower limb weakness and neurogenic EMG changes, but she lacked areflexia and had normal CK levels. For 29 years, she had been misdiagnosed with «unspecified myopathy»(G72.9). Conclusion. The findings highlight the need to include 5q SMA in the differential diagnosis of adult patients with undifferentiated neuromuscular disorders. Optimizing diagnostic algorithms and enhancing epidemiological monitoring in this age group are essential to reduce diagnostic delays.
- Open Access
Enhanced Neural Plasticity of the Primary Visual Cortex in Visual Snow Syndrome: Evidence from MEG Gamma Oscillations
Visual Snow Syndrome (VSS) is a neurological disorder characterized by persistent visual disturbances and associated symptoms. Although the neural basis of VSS remains poorly understood, it may involve increased neuronal excitability and/or altered neuroplasticity in the visual cortex, which could, in turn, affect visual gamma oscillations. An altered excitation-inhibition (E-I) balance is hypothesized to alter the modulation of gamma power and frequency by stimulation intensity, while maladaptive neuroplasticity may impact time-dependent changes in gamma power during repeated stimulation. To investigate potential alterations in E-I balance and neuroplasticity in VSS, we magnetoencephalography to record visual gamma oscillations in 26 VSS patients and 27 healthy controls. Participants were exposed to repeatedly presented high-contrast annular gratings, which were either static or drifting at varying speeds to systematically manipulate stimulation intensity. We also measured heart rate variability (HRV) during rest and repetitive visual stimulation to explore the relationship between time-dependent gamma changes and parasympathetic activation, which is known to promote activity-dependent plasticity. Our results showed no significant group differences in gamma power or frequency, nor in their modulation by drift rate, suggesting that the excitation-inhibition (E-I) balance in the primary visual cortex remains largely intact in VSS. Both groups exhibited an initial brief decrease in gamma power followed by a sustained linear increase with stimulus repetition, likely reflecting activity-dependent plasticity. HRV parameters were comparable across groups, with the parasympathetic-sympathetic balance index correlating with repetition-related increase in gamma power, further supporting the link between time-dependent gamma changes and neuroplasticity. Notably, VSS patients exhibited a steeper repetition-related increase in gamma power, indicating atypically heightened activity-dependent plasticity in this group. These findings provide the first experimental evidence suggesting that altered activity-dependent neuroplasticity plays a role in the pathophysiology of VSS. Furthermore, they identify repetition-related increases in gamma power as a potential biomarker of aberrant neuroplasticity, offering novel insights into VSS pathophysiology and potential avenues for targeted therapeutic interventions.
Open AccessEnhanced Neural Plasticity of the Primary Visual Cortex in Visual Snow Syndrome: Evidence from MEG Gamma Oscillations
Visual Snow Syndrome (VSS) is a neurological disorder characterized by persistent visual disturbances and associated symptoms. Although the neural basis of VSS remains poorly understood, it may involve increased neuronal excitability and/or altered neuroplasticity in the visual cortex, which could, in turn, affect visual gamma oscillations. An altered excitation-inhibition (E-I) balance is hypothesized to alter the modulation of gamma power and frequency by stimulation intensity, while maladaptive neuroplasticity may impact time-dependent changes in gamma power during repeated stimulation. To investigate potential alterations in E-I balance and neuroplasticity in VSS, we magnetoencephalography to record visual gamma oscillations in 26 VSS patients and 27 healthy controls. Participants were exposed to repeatedly presented high-contrast annular gratings, which were either static or drifting at varying speeds to systematically manipulate stimulation intensity. We also measured heart rate variability (HRV) during rest and repetitive visual stimulation to explore the relationship between time-dependent gamma changes and parasympathetic activation, which is known to promote activity-dependent plasticity. Our results showed no significant group differences in gamma power or frequency, nor in their modulation by drift rate, suggesting that the excitation-inhibition (E-I) balance in the primary visual cortex remains largely intact in VSS. Both groups exhibited an initial brief decrease in gamma power followed by a sustained linear increase with stimulus repetition, likely reflecting activity-dependent plasticity. HRV parameters were comparable across groups, with the parasympathetic-sympathetic balance index correlating with repetition-related increase in gamma power, further supporting the link between time-dependent gamma changes and neuroplasticity. Notably, VSS patients exhibited a steeper repetition-related increase in gamma power, indicating atypically heightened activity-dependent plasticity in this group. These findings provide the first experimental evidence suggesting that altered activity-dependent neuroplasticity plays a role in the pathophysiology of VSS. Furthermore, they identify repetition-related increases in gamma power as a potential biomarker of aberrant neuroplasticity, offering novel insights into VSS pathophysiology and potential avenues for targeted therapeutic interventions.
- Open Access
Directional motion sensitivity in people with Visual Snow Syndrome is modulated by the presence of trailing-type palinopsia
Visual Snow Syndrome (VSS) is characterized by visual perceptual distortions, potentially linked to increased neural excitability. We hypothesized that this hyperexcitability might affect motion direction sensitivity in VSS, particularly in those with trailing-type palinopsia (TTP), an atypical perception of visual motion. Using a spatial suppression paradigm, we assessed motion duration discrimination thresholds for small (1°), medium (2.5°), and large (12°) high-contrast gratings in 23 VSS and 27 control participants. Spatial Suppression Index (SSI) quantified size-dependent increases in duration thresholds. Visual Discomfort Questionnaire scores and VSS symptom ratings including TTP, afterimages, photophobia, etc. were also collected. VSS patients reported higher visual discomfort and perceptual disturbances. However, no group differences were found in duration thresholds or SSI. Notably, higher TTP scores were associated with lower duration thresholds, indicating a facilitatory effect of TTP on motion sensitivity. These findings suggest that ‘visual snow,’ the core symptom of VSS, is not linked to abnormal directional sensitivity or center-surround suppression associated with visual motion. However, the dependence of directional sensitivity on TTP emphasizes the heterogeneity of VSS, which should be considered in future neurophysiological and clinical models.
Open AccessDirectional motion sensitivity in people with Visual Snow Syndrome is modulated by the presence of trailing-type palinopsia
Visual Snow Syndrome (VSS) is characterized by visual perceptual distortions, potentially linked to increased neural excitability. We hypothesized that this hyperexcitability might affect motion direction sensitivity in VSS, particularly in those with trailing-type palinopsia (TTP), an atypical perception of visual motion. Using a spatial suppression paradigm, we assessed motion duration discrimination thresholds for small (1°), medium (2.5°), and large (12°) high-contrast gratings in 23 VSS and 27 control participants. Spatial Suppression Index (SSI) quantified size-dependent increases in duration thresholds. Visual Discomfort Questionnaire scores and VSS symptom ratings including TTP, afterimages, photophobia, etc. were also collected. VSS patients reported higher visual discomfort and perceptual disturbances. However, no group differences were found in duration thresholds or SSI. Notably, higher TTP scores were associated with lower duration thresholds, indicating a facilitatory effect of TTP on motion sensitivity. These findings suggest that ‘visual snow,’ the core symptom of VSS, is not linked to abnormal directional sensitivity or center-surround suppression associated with visual motion. However, the dependence of directional sensitivity on TTP emphasizes the heterogeneity of VSS, which should be considered in future neurophysiological and clinical models.
- 13 October 2023
- Published by Media Sphere Publishing Group in Burdenko's Journal of Neurosurgery
- Vol. 87 (5) , 104-109
New classification and approaches to the treatment of schwannomatosis
Шванноматозы — новая классификационная единица, объединяющая все наследственные заболевания, обусловленные повреждением 22-й хромосомы и приводящие к развитию множественных доброкачественных новообразований центральной и периферической нервной системы. Шванноматозы возникают в результате повреждения разных генов: NF2, SMARCB1, LZRT1 — в случае потери гетерозиготности длинного плеча 22-й хромосомы, но характеризуются сходством клинических проявлений. Молекулярная диагностика позволяет не только подтвердить диагноз, но и прогнозировать течение заболевания. Так, наиболее тяжелые клинические проявления наблюдаются у пациентов с нарушением смысловых последовательностей и сдвига рамки считывания в экзонах 2—13 гена NF2, а более благоприятное течение с небольшим количеством опухолей — у пациентов с соматическим мозаицизмом. Стереотаксическое лучевое и хирургическое лечение остаются основными опциями в лечении шванноматозов, однако появляется все больше данных эффективности таргетной терапии бевацизумабом, ингибитором фактора роста эндотелия сосудов. Бевацизумаб применяется у пациентов с двусторонними вестибулярными шванномами и высоким риском потери полезного слуха, а также для контроля роста интрамедуллярных опухолей.
- 13 October 2023
- Published by Media Sphere Publishing Group in Burdenko's Journal of Neurosurgery
- Vol. 87 (5) , 104-109
New classification and approaches to the treatment of schwannomatosis
Шванноматозы — новая классификационная единица, объединяющая все наследственные заболевания, обусловленные повреждением 22-й хромосомы и приводящие к развитию множественных доброкачественных новообразований центральной и периферической нервной системы. Шванноматозы возникают в результате повреждения разных генов: NF2, SMARCB1, LZRT1 — в случае потери гетерозиготности длинного плеча 22-й хромосомы, но характеризуются сходством клинических проявлений. Молекулярная диагностика позволяет не только подтвердить диагноз, но и прогнозировать течение заболевания. Так, наиболее тяжелые клинические проявления наблюдаются у пациентов с нарушением смысловых последовательностей и сдвига рамки считывания в экзонах 2—13 гена NF2, а более благоприятное течение с небольшим количеством опухолей — у пациентов с соматическим мозаицизмом. Стереотаксическое лучевое и хирургическое лечение остаются основными опциями в лечении шванноматозов, однако появляется все больше данных эффективности таргетной терапии бевацизумабом, ингибитором фактора роста эндотелия сосудов. Бевацизумаб применяется у пациентов с двусторонними вестибулярными шванномами и высоким риском потери полезного слуха, а также для контроля роста интрамедуллярных опухолей.